Evaluate the Use of Glibenclamide on Acute aSAH

Summary

A randomized, open-labeled, blank-controlled and prospective trial meant to evaluate the use of glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two groups, one for 3.75 mg daily intake of glibenclamide for 7 days and another as a blank contrast. General clinical data and late cognitive status will be accessed in both groups.

Timeline

Start

2021-10-19

Primary completion

2022-10-19

Completion

2022-12-01

Outcome

Missed primary endpoint

paper On days 3 and 7, there were no statistically significant differences observed in serum NSE and S100B levels between the two groups (P > 0.05). PMID 39117964 ↗

paper Treating patients with early aSAH with oral glibenclamide did not decrease levels of serum NSE and S100B PMID 39117964 ↗

Publications

• Lin Q, Zhou D, Ma J, Zhao J, Chen G, Wu L, Li T, Zhao S, Wen H, Yu H, Zhang S, Gao K, Yang R, Shi G. Efficacy and Safety of Early Treatment with Glibenclamide in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized Controlled Trial. Neurocrit Care. 2024 Dec;41(3):828-839. doi: 10.1007/s12028-024-01999-z. Epub 2024 Aug 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glyburide	Small molecule	1.25 mg	Oral

Indications